{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T14:27:18Z","timestamp":1784903238581,"version":"3.55.0"},"reference-count":110,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2021,2,27]],"date-time":"2021-02-27T00:00:00Z","timestamp":1614384000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100011912","name":"Taipei Veterans General Hospital","doi-asserted-by":"publisher","award":["V108B-032, V109D49-002-MY2-1, V109D49-002-MY2-2"],"award-info":[{"award-number":["V108B-032, V109D49-002-MY2-1, V109D49-002-MY2-2"]}],"id":[{"id":"10.13039\/501100011912","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004663","name":"Ministry of Science and Technology, Taiwan","doi-asserted-by":"publisher","award":["MOST109-2635-B-075-001"],"award-info":[{"award-number":["MOST109-2635-B-075-001"]}],"id":[{"id":"10.13039\/501100004663","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Immunotherapy, including chimeric antigen receptor (CAR) T-cell therapy, immune checkpoint inhibitors, cancer vaccines, and dendritic cell therapy, has been incorporated as a fifth modality of modern cancer care, along with surgery, radiation, chemotherapy, and target therapy. Among them, CAR T-cell therapy emerges as one of the most promising treatments. In 2017, the first two CAR T-cell drugs, tisagenlecleucel and axicabtagene ciloleucel for B-cell acute lymphoblastic leukemia (ALL) and diffuse large B-cell lymphoma (DLBCL), respectively, were approved by the Food and Drug Administration (FDA). In addition to the successful applications to hematological malignancies, CAR T-cell therapy has been investigated to potentially treat solid tumors, including pediatric brain tumor, which serves as the leading cause of cancer-associated death for children and adolescents. However, the employment of CAR T-cell therapy in pediatric brain tumors still faces multiple challenges, such as CAR T-cell transportation and expansion through the blood\u2013brain barrier, and identification of the specific target antigen on the tumor surface and immunosuppressive tumor microenvironment. Nevertheless, encouraging outcomes in both clinical and preclinical trials are coming to light. In this article, we outline the current propitious progress and discuss the obstacles needed to be overcome in order to unveil a new era of treatment in pediatric brain tumors.<\/jats:p>","DOI":"10.3390\/ijms22052404","type":"journal-article","created":{"date-parts":[[2021,2,27]],"date-time":"2021-02-27T20:55:44Z","timestamp":1614459344000},"page":"2404","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["New Era of Immunotherapy in Pediatric Brain Tumors: Chimeric Antigen Receptor T-Cell Therapy"],"prefix":"10.3390","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8660-0397","authenticated-orcid":false,"given":"Wan-Tai","family":"Wu","sequence":"first","affiliation":[{"name":"School of Medicine, National Yang Ming Chiao Tung University, Taipei 112304, Taiwan"},{"name":"Division of Pediatric Neurosurgery, Department of Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, 201, Section 2, Shih-Pai Road, Taipei 112201, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3127-201X","authenticated-orcid":false,"given":"Wen-Ying","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Taipei Veterans General Hospital, Taipei 112201, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Wei","family":"Chen","sequence":"additional","affiliation":[{"name":"School of Medicine, National Yang Ming Chiao Tung University, Taipei 112304, Taiwan"},{"name":"Division of Radiation Oncology, Department of Oncology, Taipei Veterans General Hospital, Taipei 112201, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Fu","family":"Lin","sequence":"additional","affiliation":[{"name":"School of Medicine, National Yang Ming Chiao Tung University, Taipei 112304, Taiwan"},{"name":"Department of Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei 112201, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsin-Hui","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Division of Pediatric Immunology and Nephrology, Taipei Veterans General Hospital, Taipei 112201, Taiwan"},{"name":"Department of Pediatrics, Faculty of Medicine, School of Medicine, National Yang Ming Chiao Tung University, Taipei 112304, Taiwan"},{"name":"Institute of Emergency and Critical Care Medicine, School of Medicine, National Yang Ming Chiao Tung University, Taipei 112304, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Szu-Hsien","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Plastic and Reconstructive Surgery, Taipei Veterans General Hospital, Taipei 112201, Taiwan"},{"name":"Department of Surgery, School of Medicine, National Yang Ming Chiao Tung University, Taipei 112304, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Yen","family":"Lee","sequence":"additional","affiliation":[{"name":"School of Medicine, National Yang Ming Chiao Tung University, Taipei 112304, Taiwan"},{"name":"Division of Pediatric Neurosurgery, Department of Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, 201, Section 2, Shih-Pai Road, Taipei 112201, Taiwan"},{"name":"Department of Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei 112201, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2021,2,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e42","DOI":"10.1016\/S1470-2045(18)30761-7","article-title":"Childhood cancer burden: A review of global estimates","volume":"20","author":"Bhakta","year":"2019","journal-title":"Lancet. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21590","article-title":"Cancer statistics","volume":"70","author":"Siegel","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"ref_3","unstructured":"Subramanian, S., and Ahmad, T. (2019). Cancer, Childhood Brain Tumors, StatPearls Publishing."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1111\/j.1750-3639.2008.00236.x","article-title":"Brain tumor susceptibility: The role of genetic factors and uses of mouse models to unravel risk","volume":"19","author":"Reilly","year":"2009","journal-title":"Brain Pathol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.ncl.2018.04.009","article-title":"Pediatric brain tumors","volume":"36","author":"Udaka","year":"2018","journal-title":"Neurol. Clin."},{"key":"ref_6","unstructured":"Merchant, T.E., Pollack, I.F., and Loeffler, J.S. (2020). Brain Tumors Across the Age Spectrum: Biology, Therapy, and Late Effects. Seminars in Radiation Oncology, Elsevier."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.it.2019.05.009","article-title":"Towards immunotherapy for pediatric brain tumors","volume":"40","author":"Wang","year":"2019","journal-title":"Trends Immunol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.tmrv.2019.01.005","article-title":"Risks and benefits of chimeric antigen receptor t-cell (car-t) therapy in cancer: A systematic review and meta-analysis","volume":"33","author":"Grigor","year":"2019","journal-title":"Transfus. Med. Rev."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","article-title":"Chimeric antigen receptor therapy","volume":"379","author":"June","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The basic principles of chimeric antigen receptor design","volume":"3","author":"Sadelain","year":"2013","journal-title":"Cancer Discov."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.it.2015.06.004","article-title":"Engineering car-t cells: Design concepts","volume":"36","author":"Srivastava","year":"2015","journal-title":"Trends Immunol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrc971","article-title":"Targeting tumours with genetically enhanced t lymphocytes","volume":"3","author":"Sadelain","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"6123","DOI":"10.4049\/jimmunol.167.11.6123","article-title":"Tumor-specific t cell activation by recombinant immunoreceptors: Cd3 zeta signaling and cd28 costimulation are simultaneously required for efficient il-2 secretion and can be integrated into one combined cd28\/cd3 zeta signaling receptor molecule","volume":"167","author":"Hombach","year":"2001","journal-title":"J. Immunol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1038\/icb.1975.3","article-title":"A new analysis of allogeneic interactions","volume":"53","author":"Lafferty","year":"1975","journal-title":"Aust. J. Exp. Biol. Med. Sci."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1177\/1535370215584936","article-title":"From humble beginnings to success in the clinic: Chimeric antigen receptor-modified t-cells and implications for immunotherapy","volume":"240","author":"Firor","year":"2015","journal-title":"Exp. Biol. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.4049\/jimmunol.161.6.2791","article-title":"Chimeric receptors providing both primary and costimulatory signaling in t cells from a single gene product","volume":"161","author":"Finney","year":"1998","journal-title":"J. Immunol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1158\/1078-0432.CCR-07-0674","article-title":"Genetically targeted t cells eradicate systemic acute lymphoblastic leukemia xenografts","volume":"13","author":"Brentjens","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/sj.leu.2403302","article-title":"Chimeric receptors with 4\u20131bb signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia","volume":"18","author":"Imai","year":"2004","journal-title":"Leukemia"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40364-017-0102-y","article-title":"Engineering car-t cells","volume":"5","author":"Zhang","year":"2017","journal-title":"Biomark Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/mt.2010.24","article-title":"Case report of a serious adverse event following the administration of t cells transduced with a chimeric antigen receptor recognizing ERBB2","volume":"18","author":"Morgan","year":"2010","journal-title":"Mol. Ther."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1016\/j.ymthe.2017.05.012","article-title":"Car t cells administered in combination with lymphodepletion and pd-1 inhibition to patients with neuroblastoma","volume":"25","author":"Heczey","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1517\/14712598.2015.1046430","article-title":"Trucks: The fourth generation of cars","volume":"15","author":"Chmielewski","year":"2015","journal-title":"Expert Opin. Biol. Ther."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/ni1582","article-title":"Functions of natural killer cells","volume":"9","author":"Vivier","year":"2008","journal-title":"Nat. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1002\/acg2.84","article-title":"Trucks, the fourth-generation car t cells: Current developments and clinical translation","volume":"3","author":"Chmielewski","year":"2020","journal-title":"Adv. Cell Gene Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41416-018-0325-1","article-title":"Teaching an old dog new tricks: Next-generation car t cells","volume":"120","author":"Tokarew","year":"2019","journal-title":"Br. J. Cancer"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1056\/NEJMp1711886","article-title":"Tragedy, perseverance, and chance\u2014the story of car-t therapy","volume":"377","author":"Rosenbaum","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"3322","DOI":"10.1182\/blood-2017-02-769208","article-title":"Intent-to-treat leukemia remission by cd19 car t cells of defined formulation and dose in children and young adults","volume":"129","author":"Gardner","year":"2017","journal-title":"Blood"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/bjh.13340","article-title":"Cd 19 chimeric antigen receptor t cell therapy for haematological malignancies","volume":"169","author":"Ghorashian","year":"2015","journal-title":"Br. J. Haematol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/S0140-6736(14)61403-3","article-title":"T cells expressing cd19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: A phase 1 dose-escalation trial","volume":"385","author":"Lee","year":"2015","journal-title":"Lancet"},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1407222","article-title":"Chimeric antigen receptor t cells for sustained remissions in leukemia","volume":"371","author":"Maude","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Ahmad, A., Uddin, S., and Steinhoff, M. (2020). Car-t cell therapies: An overview of clinical studies supporting their approved use against acute lymphoblastic leukemia and large b-cell lymphomas. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21113906"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with b-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1158\/1078-0432.CCR-18-2035","article-title":"Fda approval summary: Tisagenlecleucel for treatment of patients with relapsed or refractory b-cell precursor acute lymphoblastic leukemia","volume":"25","author":"Lu","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1158\/1078-0432.CCR-18-2743","article-title":"Fda approval summary: Axicabtagene ciloleucel for relapsed or refractory large b-cell lymphoma","volume":"25","author":"Bouchkouj","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1111\/imr.12773","article-title":"Car t cells for brain tumors: Lessons learned and road ahead","volume":"290","author":"Akhavan","year":"2019","journal-title":"Immunol. Rev."},{"key":"ref_36","doi-asserted-by":"crossref","unstructured":"Dai, H., Wang, Y., Lu, X., and Han, W. (2016). Chimeric antigen receptors modified t-cells for cancer therapy. JNCI J. Natl. Cancer Inst., 108.","DOI":"10.1093\/jnci\/djv439"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1016\/j.adro.2018.08.018","article-title":"Role of the immunosuppressive microenvironment in immunotherapy","volume":"3","author":"Tormoen","year":"2018","journal-title":"Adv. Radiat. Oncol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.ccell.2017.02.009","article-title":"The microenvironmental landscape of brain tumors","volume":"31","author":"Quail","year":"2017","journal-title":"Cancer Cell"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Sun, S., Hao, H., Yang, G., Zhang, Y., and Fu, Y. (2018). Immunotherapy with car-modified t cells: Toxicities and overcoming strategies. J. Immunol. Res., 2018.","DOI":"10.1155\/2018\/2386187"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1505","DOI":"10.1007\/s00262-017-2045-4","article-title":"Car t cells targeting solid tumors: Carcinoembryonic antigen (cea) proves to be a safe target","volume":"66","author":"Holzinger","year":"2017","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1016\/j.ymthe.2017.03.010","article-title":"Phase i escalating-dose trial of car-t therapy targeting cea + metastatic colorectal cancers","volume":"25","author":"Zhang","year":"2017","journal-title":"Mol. Ther."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1007\/s00262-017-2034-7","article-title":"The clinical efficacy of first-generation carcinoembryonic antigen (ceacam5)-specific car t cells is limited by poor persistence and transient pre-conditioning-dependent respiratory toxicity","volume":"66","author":"Thistlethwaite","year":"2017","journal-title":"Cancer Immunol. Immunother."},{"key":"ref_43","first-page":"674","article-title":"Gd2 chimeric antigen receptor modified t cells in synergy with sub-toxic level of doxorubicin targeting osteosarcomas","volume":"10","author":"Chulanetra","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1158\/1078-0432.CCR-14-1421","article-title":"Phase i hepatic immunotherapy for metastases study of intra-arterial chimeric antigen receptor\u2013modified t-cell therapy for cea + liver metastases","volume":"21","author":"Katz","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1001\/jamaoncol.2017.0184","article-title":"Her2-specific chimeric antigen receptor\u2014modified virus-specific t cells for progressive glioblastoma: A phase 1 dose-escalation trial","volume":"3","author":"Ahmed","year":"2017","journal-title":"JAMA Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"4062","DOI":"10.1158\/1078-0432.CCR-15-0428","article-title":"Bioactivity and safety of il13r\u03b12-redirected chimeric antigen receptor cd8 + t cells in patients with recurrent glioblastoma","volume":"21","author":"Brown","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1097\/CJI.0000000000000260","article-title":"Pilot trial of adoptive transfer of chimeric antigen receptor transduced t cells targeting egfrviii in patients with glioblastoma","volume":"42","author":"Goff","year":"2019","journal-title":"J. Immunother."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"O\u2019Rourke, D.M., Nasrallah, M.P., Desai, A., Melenhorst, J.J., Mansfield, K., Morrissette, J.J., Martinez-Lage, M., Brem, S., Maloney, E., and Shen, A. (2017). A single dose of peripherally infused egfrviii-directed car t cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma. Sci. Transl. Med., 9.","DOI":"10.1126\/scitranslmed.aaa0984"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1188\/16.CJON.S1.2-8","article-title":"Glioblastoma: Overview of disease and treatment","volume":"20","author":"Davis","year":"2016","journal-title":"Clin. J. Oncol. Nurs."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"DeNunzio, N.J., and Yock, T.I. (2020). Modern radiotherapy for pediatric brain tumors. Cancers, 12.","DOI":"10.3390\/cancers12061533"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1002\/ajh.25418","article-title":"An introduction to chimeric antigen receptor (car) t-cell immunotherapy for human cancer","volume":"94","author":"Feins","year":"2019","journal-title":"Am. J. Hematol."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1582","DOI":"10.3389\/fonc.2020.01582","article-title":"Car t cell therapy for pediatric brain tumors","volume":"10","author":"Patterson","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"5957","DOI":"10.1158\/0008-5472.CAN-06-4309","article-title":"Regression of experimental medulloblastoma following transfer of her2-specific t cells","volume":"67","author":"Ahmed","year":"2007","journal-title":"Cancer Res."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s40425-018-0340-z","article-title":"Durable regression of medulloblastoma after regional and intravenous delivery of anti-her2 chimeric antigen receptor t cells","volume":"6","author":"Nellan","year":"2018","journal-title":"J. Immunother. Cancer"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1158\/1078-0432.CCR-18-0432","article-title":"Car t cells targeting b7-h3, a pan-cancer antigen, demonstrate potent preclinical activity against pediatric solid tumors and brain tumors","volume":"25","author":"Majzner","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"3834","DOI":"10.1158\/1078-0432.CCR-12-0715","article-title":"Development of an fc-enhanced anti-b7-h3 monoclonal antibody with potent antitumor activity","volume":"18","author":"Loo","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/s41591-020-0821-8","article-title":"Locoregionally administered b7-h3-targeted car t cells for treatment of atypical teratoid\/rhabdoid tumors","volume":"26","author":"Theruvath","year":"2020","journal-title":"Nat. Med."},{"key":"ref_58","first-page":"3","article-title":"Immunotherapy targets in pediatric cancer","volume":"2","author":"Orentas","year":"2012","journal-title":"Front. Oncol."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"3337","DOI":"10.1158\/0008-5472.CAN-17-3140","article-title":"Adoptive immunotherapy using prame-specific t cells in medulloblastoma","volume":"78","author":"Orlando","year":"2018","journal-title":"Cancer Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1093\/neuonc\/nox116","article-title":"Cd70, a novel target of car t-cell therapy for gliomas","volume":"20","author":"Jin","year":"2018","journal-title":"Neuro-Oncology"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1158\/2326-6066.CIR-15-0060","article-title":"Car t cells targeting podoplanin reduce orthotopic glioblastomas in mouse brains","volume":"4","author":"Shiina","year":"2016","journal-title":"Cancer Immunol. Res."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/s41591-018-0006-x","article-title":"Potent antitumor efficacy of anti-gd2 car t cells in h3-k27m + diffuse midline gliomas","volume":"24","author":"Mount","year":"2018","journal-title":"Nat. Med."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"6050","DOI":"10.1182\/blood-2011-05-354449","article-title":"Antitumor activity and long-term fate of chimeric antigen receptor-positive t cells in patients with neuroblastoma","volume":"118","author":"Louis","year":"2011","journal-title":"Blood"},{"key":"ref_64","doi-asserted-by":"crossref","unstructured":"Thomas, S., Straathof, K., Himoudi, N., Anderson, J., and Pule, M. (2016). An optimized gd2-targeting retroviral cassette for more potent and safer cellular therapy of neuroblastoma and other cancers. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0152196"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1038\/nm.1882","article-title":"Virus-specific t cells engineered to coexpress tumor-specific receptors: Persistence and antitumor activity in individuals with neuroblastoma","volume":"14","author":"Pule","year":"2008","journal-title":"Nat. Med."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.stemcr.2018.07.010","article-title":"In Vivo expansion of cancer stemness affords novel cancer stem cell targets: Malignant rhabdoid tumor as an example","volume":"11","author":"Golan","year":"2018","journal-title":"Stem Cell Rep."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"462","DOI":"10.21037\/atm.2017.09.11","article-title":"Antibody-drug conjugate targeting protein tyrosine kinase 7, a receptor tyrosine kinase-like molecule involved in wnt and vascular endothelial growth factor signaling: Effects on cancer stem cells, tumor microenvironment and whole-body homeostasis","volume":"5","author":"Katoh","year":"2017","journal-title":"Ann. Transl. Med."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1158\/1541-7786.MCR-16-0432","article-title":"Therapeutic targeting of ptk7 is cytotoxic in atypical teratoid rhabdoid tumors","volume":"15","author":"Messerli","year":"2017","journal-title":"Mol. Cancer Res."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Haydar, D., Houke, H., Chiang, J., Yi, Z., Od\u00e9, Z., Caldwell, K., Zhu, X., Mercer, K.S., Stripay, J.L., and Shaw, T.I. (2020). Cell surface antigen profiling of pediatric brain tumors: B7-h3 is consistently expressed and can be targeted via local or systemic car t-cell delivery. Neuro-Oncology.","DOI":"10.1093\/neuonc\/noaa278"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"3036","DOI":"10.1172\/JCI83416","article-title":"Tandem car t cells targeting her2 and il13r\u03b12 mitigate tumor antigen escape","volume":"126","author":"Hegde","year":"2016","journal-title":"J. Clin. Investig."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1093\/neuonc\/nox182","article-title":"Trivalent car t cells overcome interpatient antigenic variability in glioblastoma","volume":"20","author":"Bielamowicz","year":"2018","journal-title":"Neuro-Oncology"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/s41591-020-0827-2","article-title":"Locoregional delivery of car t cells to the cerebrospinal fluid for treatment of metastatic medulloblastoma and ependymoma","volume":"26","author":"Donovan","year":"2020","journal-title":"Nat. Med."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1038\/mt.2013.185","article-title":"Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred t cells in glioblastoma","volume":"21","author":"Hegde","year":"2013","journal-title":"Mol. Ther."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"2050","DOI":"10.1200\/JCO.2013.54.0526","article-title":"Antigen-specific immune responses and clinical outcome after vaccination with glioma-associated antigen peptides and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in children with newly diagnosed malignant brainstem and nonbrainstem gliomas","volume":"32","author":"Pollack","year":"2014","journal-title":"J. Clin. Oncol."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s11060-012-0998-x","article-title":"Increased expression of tumor-associated antigens in pediatric and adult ependymomas: Implication for vaccine therapy","volume":"111","author":"Yeung","year":"2013","journal-title":"J. Neurooncol."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1186\/s12967-018-1746-6","article-title":"Identification of a novel role of il-13r\u03b12 in human glioblastoma multiforme: Interleukin-13 mediates signal transduction through ap-1 pathway","volume":"16","author":"Bhardwaj","year":"2018","journal-title":"J. Transl. Med."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41598-019-39018-3","article-title":"Interleukin-13 receptor \u03b12 is a novel marker and potential therapeutic target for human melanoma","volume":"9","author":"Okamoto","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.1038\/s41388-020-1208-5","article-title":"Egfrviii upregulates DNA mismatch repair resulting in increased temozolomide sensitivity of mgmt promoter methylated glioblastoma","volume":"39","author":"Struve","year":"2020","journal-title":"Oncogene"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12967-020-02598-0","article-title":"Chimeric antigen receptor t-cell therapy in glioblastoma: Charging the t cells to fight","volume":"18","author":"Land","year":"2020","journal-title":"J. Transl. Med."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","article-title":"Regression of glioblastoma after chimeric antigen receptor t-cell therapy","volume":"375","author":"Brown","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.7150\/ijbs.41105","article-title":"B7-h3, a checkpoint molecule, as a target for cancer immunotherapy","volume":"16","author":"Yang","year":"2020","journal-title":"Int. J. Biol. Sci."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"7080","DOI":"10.18632\/oncotarget.27389","article-title":"Egfr806-car t cells selectively target a tumor-restricted egfr epitope in glioblastoma","volume":"10","author":"Ravanpay","year":"2019","journal-title":"Oncotarget"},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Nazha, B., Inal, C., and Owonikoko, T.K. (2020). Disialoganglioside gd2 expression in solid tumors and role as a target for cancer therapy. Front. Oncol., 10.","DOI":"10.3389\/fonc.2020.01000"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor t-cell therapy-assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1182\/blood-2017-06-793141","article-title":"Kinetics and biomarkers of severe cytokine release syndrome after cd19 chimeric antigen receptor-modified t-cell therapy","volume":"130","author":"Hay","year":"2017","journal-title":"Blood"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Y\u00e1\u00f1ez, L., Alarc\u00f3n, A., S\u00e1nchez-Escamilla, M., and Perales, M.-A. (2020). How i treat adverse effects of car-t cell therapy. ESMO Open, 4.","DOI":"10.1136\/esmoopen-2020-000746"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"Astct consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol. Blood Marrow Transplant."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"297","DOI":"10.3324\/haematol.2019.229781","article-title":"Management of adults and children undergoing chimeric antigen receptor t-cell therapy: Best practice recommendations of the european society for blood and marrow transplantation (ebmt) and the joint accreditation committee of isct and ebmt (jacie)","volume":"105","author":"Ibrahim","year":"2020","journal-title":"Haematologica"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"6","DOI":"10.2478\/ahp-2020-0003","article-title":"Car-t cell therapy\u2014toxicity and its management","volume":"51","author":"Gil","year":"2020","journal-title":"Acta Haematol. Pol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41571-018-0075-2","article-title":"Management guidelines for paediatric patients receiving chimeric antigen receptor t cell therapy","volume":"16","author":"Mahadeo","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s11060-012-1021-2","article-title":"B7-h3, a potential therapeutic target, is expressed in diffuse intrinsic pontine glioma","volume":"111","author":"Zhou","year":"2013","journal-title":"J. Neuro-Oncology"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"4817","DOI":"10.1182\/blood-2011-04-348540","article-title":"Safety and persistence of adoptively transferred autologous cd19-targeted t cells in patients with relapsed or chemotherapy refractory b-cell leukemias","volume":"118","author":"Brentjens","year":"2011","journal-title":"Blood"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/s41591-019-0564-6","article-title":"Clinical lessons learned from the first leg of the car t cell journey","volume":"25","author":"Majzner","year":"2019","journal-title":"Nat. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1158\/1535-7163.MCT-11-0519","article-title":"Single-chain antibody-based immunotoxins targeting her2\/neu: Design optimization and impact of affinity on antitumor efficacy and off-target toxicity","volume":"11","author":"Cao","year":"2012","journal-title":"Mol. Cancer Ther."},{"key":"ref_95","first-page":"372","article-title":"Mechanisms of resistance to car t cell therapy","volume":"16","author":"Shah","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"732413","DOI":"10.1155\/2011\/732413","article-title":"Challenges in immunotherapy presented by the glioblastoma multiforme microenvironment","volume":"2011","author":"Jackson","year":"2011","journal-title":"Clin. Dev. Immunol."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"5636","DOI":"10.1158\/1078-0432.CCR-13-0458","article-title":"Anti-pd-1 antibody therapy potently enhances the eradication of established tumors by gene-modified t cells","volume":"19","author":"John","year":"2013","journal-title":"Clin. Cancer Res."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.3389\/fimmu.2020.01109","article-title":"Car-t cells hit the tumor microenvironment: Strategies to overcome tumor escape","volume":"11","author":"Palazon","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1002\/JLB.1MR0520-746R","article-title":"Surmounting the obstacles that impede effective car t cell trafficking to solid tumors","volume":"108","author":"Donnadieu","year":"2020","journal-title":"J. Leukoc. Biol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1038\/mtna.2013.32","article-title":"Tancar: A novel bispecific chimeric antigen receptor for cancer immunotherapy","volume":"2","author":"Grada","year":"2013","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2444","DOI":"10.1158\/1078-0432.CCR-19-1835","article-title":"Enhancing chimeric antigen receptor t cell efficacy in solid tumors","volume":"26","author":"Reppel","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1097\/JCMA.0000000000000358","article-title":"Emerging trends in gene-modified-based chimeric antigen receptor-engineered t-cellular therapy for malignant tumors: The lesson from leukemia to pediatric brain tumors","volume":"83","author":"Lin","year":"2020","journal-title":"J. Chin. Med. Assoc."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"3718","DOI":"10.1158\/0008-5472.CAN-18-0306","article-title":"Nanoparticles that reshape the tumor milieu create a therapeutic window for effective t-cell therapy in solid malignancies","volume":"78","author":"Zhang","year":"2018","journal-title":"Cancer Res."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Meister, S.W., Hjelm, L.C., Dannemeyer, M., Tegel, H., Lindberg, H., St\u00e5hl, S., and L\u00f6fblom, J. (2020). An affibody molecule is actively transported into the cerebrospinal fluid via binding to the transferrin receptor. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21082999"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1158\/2159-8290.CD-15-1020","article-title":"Convergence of acquired mutations and alternative splicing of cd19 enables resistance to cart-19 immunotherapy","volume":"5","author":"Sotillo","year":"2015","journal-title":"Cancer Discov."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Lin, W.-Y., Wang, H.-H., Chen, Y.-W., Lin, C.-F., Fan, H.-C., and Lee, Y.-Y. (2020). Gene modified car-t cellular therapy for hematologic malignancies. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21228655"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1182\/blood-2012-05-431718","article-title":"Il-7 and il-15 instruct the generation of human memory stem t cells from naive precursors","volume":"121","author":"Cieri","year":"2013","journal-title":"Blood"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/nm.2446","article-title":"A human memory t cell subset with stem cell-like properties","volume":"17","author":"Gattinoni","year":"2011","journal-title":"Nat. Med."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nm.4478","article-title":"A novel chimeric antigen receptor containing a jak\u2013stat signaling domain mediates superior antitumor effects","volume":"24","author":"Kagoya","year":"2018","journal-title":"Nat. Med."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1182\/blood-2014-01-552174","article-title":"Closely related t-memory stem cells correlate with in vivo expansion of car.Cd19-t cells and are preserved by IL-7 and IL-15","volume":"123","author":"Xu","year":"2014","journal-title":"Blood"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/5\/2404\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T05:30:12Z","timestamp":1760160612000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/22\/5\/2404"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,27]]},"references-count":110,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2021,3]]}},"alternative-id":["ijms22052404"],"URL":"https:\/\/doi.org\/10.3390\/ijms22052404","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,27]]}}}